New research indicates a simple blood test could detect the deadliest brain tumour in the future
Archived: 2026-04-23 17:17
New research indicates a simple blood test could detect the deadliest brain tumour in the future
Skip to main content
Skip to navigation
|
Skip to main content
|
Skip to footer
Newsroom
Contact us
Michael Addelman
News and Media Relations Officer and animal research comms lead- Faculty of Biology, Medicine, and Health
michael.addelman@manchester.ac.uk
+44 (0)161 275 2111
/
+44 (0)7717 881567
Register for news releases (journalists only)
opens in new window
Social media
Visit our LinkedIn page
(opens in new window)
Visit our Facebook page
(opens in new window)
(opens in new window)
Latest news
23
Apr
2026
-
Manchester engineers boost sustainable acrylic acid production using next‑generation membrane reactor
23
Apr
2026
-
Applications open for the 2026 return of Ideas with Impact Awards
23
Apr
2026
-
RLUK 2026, and N8 CIR Digital Research Infrastructure Retreat 2026
23
Apr
2026
-
Simon Sadler’s visit to see the Sadler Scholars at The University of Manchester
23
Apr
2026
-
New Faculty of Humanities Vice-Dean for Teaching, Learning and Students appointed at the University of Manchester
22
Apr
2026
-
Manchester hosts international conference on English pronunciation for first time
Further reading
Study at The University of Manchester
opens in new window
16
March
2026
|
09:00
Europe/London
New research indicates a simple blood test could detect the deadliest brain tumour in the future
Researchers in Manchester have developed an experimental method that shows potential for accurately detecting the most common and aggressive form of brain cancer in adults, known as glioblastoma, from the blood.
This pioneering study, led by scientists at the University of Manchester and involving teams in Denmark, has been published in
Neuro-oncology Advances
In what is considered a major breakthrough in the battle against brain cancer, scientists have found early evidence that a pair of proteins in the blood may help identify glioblastoma with high accuracy and provide insights into how the disease responds to treatment.
Glioblastoma is notorious for late diagnosis, rapid progression, resistance to treatment and extreme biological complexity. At present, diagnosis and follow-up rely largely on MRI scans and invasive surgical biopsies, which can miss early changes and cannot be repeated frequently. As a result, clinicians often struggle to determine in real time whether a treatment is working or whether the tumour is beginning to return.
The new research shows that two blood-borne proteins – coagulation factor IX (F9) and cartilage oligomeric matrix protein (COMP) – form a powerful “dual-marker” signature that distinguishes patients with glioblastoma from healthy individuals with high accuracy (more than 90%). In samples taken from patients during surgery, radiotherapy and chemotherapy, the markers showed dynamic changes, reflecting treatment response and disease progression.
Professor
Petra Hamerlik
, The Brain Tumour Charity chair of Translational Neuro-Oncology at The University of Manchester, who led the study, said: “Glioblastoma is one of the most devastating cancers we face. Late detection is among the contributing factors to poor outcomes and a source of anxiety our patients face leading up to their diagnosis. The lack of reliable tests has been a major barrier to earlier diagnosis and treatment response monitoring. What is remarkable about our findings is that, despite these tumours being very different in genetic make-up, and constantly evolving, the signal in the blood is stable, robust and highly informative. We hope that once validated, this simple blood test may pave the way for earlier diagnosis and more precise monitoring of patients during and after therapy.
“Our dual-marker blood test achieved diagnostic accuracy greater than 90 percent and continued to perform just as well when the disease returned. This opens the door to a future where we can follow the tumour’s behaviour through a simple blood sample, complement brain scans, and potentially recognise when the treatment isn’t working and the cancer returns much earlier than is currently possible. We still have a long way to go before we would see this used in clinic, but it’s a very promising and exciting development in neuro-oncology research.”
Photo_2025 Petra
Download Media Kit
Preparing your download...
Download
An error occurred while preparing your download
“
Our dual-marker blood test achieved diagnostic accuracy greater than 90 percent and continued to perform just as well when the disease returned. This opens the door to a future where we can follow the tumour’s behaviour through a simple blood sample, complement brain scans, and potentially recognise when the treatment isn’t working and the cancer returns much earlier than is currently possible. We still have a long way to go before we would see this used in clinic, but it’s a very promising and exciting development in neuro-oncology research
Professor Petra Hamerlik
„
Follow me on Facebook
(opens in new window)
Add me on LinkedIn
(opens in new window)
Dr Simon Newman, Chief Scientific Officer at The Brain Tumour Charity, said: “We are immensely proud to support Petra’s role as The Brain Tumour Charity’s Chair of Translational Neuro-Oncology through a grant worth £1.35 million. Early and accurate diagnosis is absolutely critical for people with brain tumours, yet current tools are limited and often invasive. This research therefore marks a significant step towards a simple blood test that could help clinicians detect glioblastoma and monitor how patients are responding to treatment in real time.”
Professor Hamerlik, who is also the brain tumour lead for
Geoffrey Jefferson Brain Research Centre
concluded: “While validation of this finding is ongoing with the generous contribution of UK patients who kindly donated their blood for this research, our results strongly support the development of a clinically accessible blood test for glioblastoma. Ultimately, this could help doctors make more informed treatment decisions, reduce the need for repeated invasive procedures, and, most importantly, give patients and families clearer, earlier answers.”
The study was co-funded by The Brain Tumour Charity and conducted at The University of Manchester and the Manchester Cancer Research Centre (MCRC), reinforcing Manchester’s leading role in translational neuro-oncology research. The Danish Cancer Society and NovoNordisk Foundation in Denmark also part-funded this study.
The paper
Non-Invasive Detection and Monitoring of Glioblastoma Subtypes via Dual-Marker Plasma Proteomics
DOI
https://doi.org/10.1093/noajnl/vdag015
Philanthropic support has been central to enabling this research. The University is proud to partner with the Brain Tumour Charity and a number of individual donors who support Petra and her team's work. Find out more about how supporting Manchester drives impact across our research here:
Challenge Accepted
Share this page
New research indicates a simple blood test could detect the deadliest brain tumour in the future
Share on: X
Share on: Facebook
Share on: LinkedIn
Close menu
Home
About
News
Newsroom
News Archive
Media Library
Skip to main content
Skip to navigation
|
Skip to main content
|
Skip to footer
Newsroom
Contact us
Michael Addelman
News and Media Relations Officer and animal research comms lead- Faculty of Biology, Medicine, and Health
michael.addelman@manchester.ac.uk
+44 (0)161 275 2111
/
+44 (0)7717 881567
Register for news releases (journalists only)
opens in new window
Social media
Visit our LinkedIn page
(opens in new window)
Visit our Facebook page
(opens in new window)
(opens in new window)
Latest news
23
Apr
2026
-
Manchester engineers boost sustainable acrylic acid production using next‑generation membrane reactor
23
Apr
2026
-
Applications open for the 2026 return of Ideas with Impact Awards
23
Apr
2026
-
RLUK 2026, and N8 CIR Digital Research Infrastructure Retreat 2026
23
Apr
2026
-
Simon Sadler’s visit to see the Sadler Scholars at The University of Manchester
23
Apr
2026
-
New Faculty of Humanities Vice-Dean for Teaching, Learning and Students appointed at the University of Manchester
22
Apr
2026
-
Manchester hosts international conference on English pronunciation for first time
Further reading
Study at The University of Manchester
opens in new window
16
March
2026
|
09:00
Europe/London
New research indicates a simple blood test could detect the deadliest brain tumour in the future
Researchers in Manchester have developed an experimental method that shows potential for accurately detecting the most common and aggressive form of brain cancer in adults, known as glioblastoma, from the blood.
This pioneering study, led by scientists at the University of Manchester and involving teams in Denmark, has been published in
Neuro-oncology Advances
In what is considered a major breakthrough in the battle against brain cancer, scientists have found early evidence that a pair of proteins in the blood may help identify glioblastoma with high accuracy and provide insights into how the disease responds to treatment.
Glioblastoma is notorious for late diagnosis, rapid progression, resistance to treatment and extreme biological complexity. At present, diagnosis and follow-up rely largely on MRI scans and invasive surgical biopsies, which can miss early changes and cannot be repeated frequently. As a result, clinicians often struggle to determine in real time whether a treatment is working or whether the tumour is beginning to return.
The new research shows that two blood-borne proteins – coagulation factor IX (F9) and cartilage oligomeric matrix protein (COMP) – form a powerful “dual-marker” signature that distinguishes patients with glioblastoma from healthy individuals with high accuracy (more than 90%). In samples taken from patients during surgery, radiotherapy and chemotherapy, the markers showed dynamic changes, reflecting treatment response and disease progression.
Professor
Petra Hamerlik
, The Brain Tumour Charity chair of Translational Neuro-Oncology at The University of Manchester, who led the study, said: “Glioblastoma is one of the most devastating cancers we face. Late detection is among the contributing factors to poor outcomes and a source of anxiety our patients face leading up to their diagnosis. The lack of reliable tests has been a major barrier to earlier diagnosis and treatment response monitoring. What is remarkable about our findings is that, despite these tumours being very different in genetic make-up, and constantly evolving, the signal in the blood is stable, robust and highly informative. We hope that once validated, this simple blood test may pave the way for earlier diagnosis and more precise monitoring of patients during and after therapy.
“Our dual-marker blood test achieved diagnostic accuracy greater than 90 percent and continued to perform just as well when the disease returned. This opens the door to a future where we can follow the tumour’s behaviour through a simple blood sample, complement brain scans, and potentially recognise when the treatment isn’t working and the cancer returns much earlier than is currently possible. We still have a long way to go before we would see this used in clinic, but it’s a very promising and exciting development in neuro-oncology research.”
Photo_2025 Petra
Download Media Kit
Preparing your download...
Download
An error occurred while preparing your download
“
Our dual-marker blood test achieved diagnostic accuracy greater than 90 percent and continued to perform just as well when the disease returned. This opens the door to a future where we can follow the tumour’s behaviour through a simple blood sample, complement brain scans, and potentially recognise when the treatment isn’t working and the cancer returns much earlier than is currently possible. We still have a long way to go before we would see this used in clinic, but it’s a very promising and exciting development in neuro-oncology research
Professor Petra Hamerlik
„
Follow me on Facebook
(opens in new window)
Add me on LinkedIn
(opens in new window)
Dr Simon Newman, Chief Scientific Officer at The Brain Tumour Charity, said: “We are immensely proud to support Petra’s role as The Brain Tumour Charity’s Chair of Translational Neuro-Oncology through a grant worth £1.35 million. Early and accurate diagnosis is absolutely critical for people with brain tumours, yet current tools are limited and often invasive. This research therefore marks a significant step towards a simple blood test that could help clinicians detect glioblastoma and monitor how patients are responding to treatment in real time.”
Professor Hamerlik, who is also the brain tumour lead for
Geoffrey Jefferson Brain Research Centre
concluded: “While validation of this finding is ongoing with the generous contribution of UK patients who kindly donated their blood for this research, our results strongly support the development of a clinically accessible blood test for glioblastoma. Ultimately, this could help doctors make more informed treatment decisions, reduce the need for repeated invasive procedures, and, most importantly, give patients and families clearer, earlier answers.”
The study was co-funded by The Brain Tumour Charity and conducted at The University of Manchester and the Manchester Cancer Research Centre (MCRC), reinforcing Manchester’s leading role in translational neuro-oncology research. The Danish Cancer Society and NovoNordisk Foundation in Denmark also part-funded this study.
The paper
Non-Invasive Detection and Monitoring of Glioblastoma Subtypes via Dual-Marker Plasma Proteomics
DOI
https://doi.org/10.1093/noajnl/vdag015
Philanthropic support has been central to enabling this research. The University is proud to partner with the Brain Tumour Charity and a number of individual donors who support Petra and her team's work. Find out more about how supporting Manchester drives impact across our research here:
Challenge Accepted
Share this page
New research indicates a simple blood test could detect the deadliest brain tumour in the future
Share on: X
Share on: Facebook
Share on: LinkedIn
Close menu
Home
About
News
Newsroom
News Archive
Media Library